Avecho Biotechnology (ASX:AVE) - CEO, Dr Paul Gavin
CEO, Dr Paul Gavin
Source: Avecho Biotechnology
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Avecho (AVE) kicks off enrolment for its phase one human clinical trial measuring CBD absorption
  • The phase one pharmacokinetic study has been designed to look into the absorption profile of cannabidiol from its CBD soft-gel product
  • Sixteen subjects in the study will receive two separate doses over a two-week period, with medicating set to start in early October
  • The company says it’s excited to see how the treatment performs in human studies
  • Avecho shares last traded at 1.9 cents at 12:50 pm AEST

Avecho (AVE) has kicked off enrolment for its phase one human clinical trial measuring CBD absorption.

The phase one pharmacokinetic study has been designed to look into the absorption profile of cannabidiol from its CBD soft-gel product.

The trials will assess Avecho’s 75 milligram and 150 milligram CBD soft-gel products. The sixteen subjects in the study will receive two separate doses over a two-week period, with medicating set to start in early October.

The study is said to support Avecho’s strategic focus of developing pharmaceutical CBD products that leverage its proprietary TPM formulations.

The study has been designed to form a key piece of a future regulatory submission, as well as ongoing research and development for Avecho’s CBD product portfolio.

“We are delighted to progress enrolment of healthy volunteers for this study, and to commence formal clinical assessment of Avecho’s CBD soft-gel product,” said Avecho CEO, Dr Paul Gavin.

“We are excited to see how it performs in human studies.”

Results from the trials will also be used to support development and licensing arrangements with third parties, in the hopes to further expand into additional territories and new markets.

Avecho shares last traded at 1.9 cents at 12:50 pm AEST.

AVE by the numbers
More From The Market Herald

" Alterity Therapeutics (ASX:ATH) doses first patient in MSA trial

Alterity Therapeutics (ASX:ATH) doses its first patient in a clinical trial for a rare Parkinsonian disorder.

" Beamtree (ASX:BMT) signs A$10.1m RippleDown contract with Ampath

Beamtree (ASX:BMT) has signed a US$7 million (A$10.1 million) five-year contract with Ampath for its RippleDown…
Beamtree (ASX:BMT) - CEO, Tim Kelsey

" Beamtree (ASX:BMT) accelerates international growth with first NHS contracts

Beamtree (ASX:BMT) secures its first NHS (National Health Service) contracts worth about $540,000 in combined annual…
Beamtree (ASX:BMT) - CEO, Tim Kelsey

" Beamtree (ASX:BMT) sees 91pc boost in revenue

Health data analytics company Beamtree (ASX:BMT) has reported a 91 per cent boost in group revenue…